Background：LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib.
LRRC15 is highly expressed in a variety of solid tumors.
LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma).
LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells.
These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin.
ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.
仕様
サイズ：25ug
Source：Biotinylated Mouse LRRC15, His,Avitag (LR5-M82E6) is expressed from human 293 cells (HEK293). It contains AA Tyr 22 - Gly 536 (Accession # Q80X72-1).
Molecule：LRRC15
Synonyms：Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib
Species：Mouse
Tag：His Tag & Avi Tag
Expression Systems：HEK293
Expression Rigeion：Tyr 22 - Gly 536
Conjugate：Precision Avi
Accession：NP_083249.1
Molecular Weight：61.2 kDa
Characteristics：This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag). The protein has a calculated MW of 61.2 kDa. The protein migrates as 70-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level：Less than 1.0 EU per ug by the LAL method.
